Two Presentations at ASH 2025 to highlight preclinical data and clinical development plans for GB3226, a novel dual ENL-YEATS and FLT3 inhibitor ...
Biodexa Announces Approval of CTA in Europe for Phase 3 Serenta Trial in FAP. First European patient expected to be enrolled in 4Q 2025. Addressable US - Europea ...
In recognition of National Family Caregivers Month, a new national study commissioned by Restaura and conducted by Age of Majority reveals how America's caregiving landscape is being redefined by Gen ...
Submission announced on the sidelines of Gateway Gulf, marks a key milestone in Beyon’s USD 1.5 billion innovation hub to be built at its Hamala headquarters ...
Enliven Therapeutics, Inc. (Enliven or the Company) , a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced the Company ...
November 3, 2025 Biodexa Announces Approval of CTA in Europe for Phase 3 Serenta Trial in FAP First European patient expected to be enrolled in 4Q 2025 Addressable US - European Market Put at $7 Billi ...
Early-stage lung adenocarcinoma alters DNA methylation, mRNA transcription, and protein expression in adjacent tissues, exhibiting either steep changes at the tumor boundaries or shallow changes ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback